Anti-Helicobacter pylori effects of IgY from egg york of immunized hens by Yang, Yun-Hui et al.
55
Anti-Helicobacter pylori effects of IgY from egg york of
immunized hens
Yun-Hui Yang
1, Dongsun Park
1, Goeun Yang
1, Sun Hee Lee
1, Dae Kwon Bae
1, Jangbeen Kyung
1,
Dajeong Kim
1, Ehn-Kyoung Choi
1, Jae-Cheol Son
2, Seock-Yeon Hwang
3, Yun-Bae Kim
1*
1College of Veterinary Medicine, Chungbuk National University, Cheongju, Korea
2Department of Clinical Laboratory Medicine, Chungbuk National University Hospital, Cheongju, Korea
3Department of Biomedical Laboratory Science, Daejeon University, Daejeon, Korea
Effects of egg york containing IgY specific for Helicobacter pylori on the bacterial growth and intragastric
infection were investigated in comparison with a proton-pump inhibitor pantoprazole. For in vitro anti-
bacterial activity test, H. pylori (1×10
8 CFU/mL) was incubated with a serially diluted IgY for 3 days. As a
result, IgY fully inhibited the bacterial growth at 16 mg/mL, which was determined to a minimal inhibitory
concentration.  In vivo elimination study, male C57BL/6 mice were infected with the bacteria by
intragastric inoculation (1×10
8 CFU/mouse) 3 times at 2-day intervals, and 2 weeks later, orally treated
twice a day with 50, 100, 200 or 500 mg/kg IgY for 18 days. After the final administration, biopsy sample
of the gastric mucosa was assayed for the bacterial identification via urease, oxidase, catalase, nitrate
reduction and H2S tests in addition to microscopic examination for mucosal inflammation. In CLO kit test,
75, 50, 12.5 and 12.5% of the animals revealed positive reaction following treatment with 50, 100, 200
and 500 mg/kg IgY, respectively, resulting in a superior efficacy at 200 mg/kg than 30 mg/kg pantoprazole
that displayed 75% elimination. The CLO test results were confirmed by bacterial identification.
Microscopic examination revealed that H. pylori infection caused severe gastric mucosal inflammation,
which were not observed in the CLO-negative mice following treatment with IgY or pantoprazole. Taken
together, IgY inhibited the growth of H. pylori, and improved gastritis and villi injuries by eliminating the
bacteria from the stomach. The results indicate that IgY could be a good candidate overcoming tolerance
of antibiotics for the treatment of H. pylori-mediated gastric ulcers.
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Peptic ulcers are injury of the mucosal area immersed
in gastric acid and pepsin, wherein the area is covered
normally with mucin secreted from mucus cells [1,2].
So, erosions and ulcers are caused by various factors
including gastric oversecretion and retention, weakening
and depleting agents of mucin layer, blood flow
disturbances, and mucosal injury and inflammation [1-
4]. The ulcer–inducing agents include non-steroidal anti-
inflammatory drugs (NSAIDs) that block production
prostaglandins (PGs), leading to mucin depletion and
blood flow disturbances [5-9], alcohols [7,8,10], stresses
[4,7,8], gastric oversecretion and retention [7,8], gastric
hypermotility and acetic acid accumulation [8,11-14]
and bacterial (Helicobacter pylori) infection [1,2,15-17].
It is well known that H. pylori, closely associated with
peptic ulcers, chronic active gastritis and gastric malignancies,
is a key factor for recurrence and aggravation of ulcers
as well as development to gastric malignancies [18-20].
It is believed that H. pylori aggravates ulcers by
continuously stimulating gastric secretion [21,22]. Thus,
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elimination of H. pylori is a key point for ulcer treatment
in adults exhibiting a high incidence [1,2,15,17,23,24].
For the therapy of H. pylori-mediated gastritis and ulcers,
triple therapies (omeprazole+clerithromycin+amoxicillin
or omeprazole+clerithromycin+metronidazole) composed
of proton-pump inhibitors (pantoprazole, omeprazole,
lansoprazole, etc) and antibiotics (clarithromycin,
metronidazole, amoxicillin, etc) have been recommended
[2]. However, antibiotics used for triple therapy are
becoming ineffective due to a rapidly-increasing
tolerance of the bacteria [25].
In the present study, in vitro anti-bacterial activity and
in vivo bacteria-eliminating efficacy of IgY specific for
H. pylori obtained by immunization to hens were
investigated in comparison with a proton-pump inhibitor
pantoprazole. It has been reported that proton-pump
inhibitors such as pantoprazole inhibit gastric secretion
[26,27], protect parietal cells [28-30], and suppress
growth of H. pylori [31-33].
Materials and Methods
Materials
Ig-Guard Helico
®, egg york containing anti-H. pylori
IgY (9.5 mg/g), obtained from immunized hens, were
from ADbiotech Co., Ltd. (Chuncheon, Korea). In brief,
H. pylori (KCTC12083) was cultured in Brucella agar
containing 5% fetal bovine serum (FBS) at a 10% CO2
incubator (37
oC), further in Brucella broth, and
inactivated in 0.3% formalin for 12 hours. The inactivated
antigen was centrifuged at 9,000 rpm for 15 min (4), and
the pellet was adjusted to optical density (OD) of 0.5 at
410 nm. After mixing the antigen with ISA 70 adjuvant
(3:7), the vaccine sample (3 mL) was intramuscularly
inoculated to 22-week-old Hy-Line brown hens 3 times
at 3-week intervals followed by boosting vaccination 35
days after the final inoculation. IgY-containing egg york
was stored at −70
oC until use.
H. pylori culture and identification
H. pylori (ATCC49503) was obtained from American
Type Culture Collection (Manassas, VA, USA), and
cultured on brain heart infusion (BHI) broth in an
anaerobic chamber with 10% CO2, 5% O2 and 85% N2
at 37
oC with enough humidity.
In vitro anti-bacterial activity
The inhibitory capacity of IgY against the growth of
H. pylori was assessed using agar-dilution method [32].
In brief, serially diluted IgY was added to Mueller
Hinton agar containing 10% FBS, and H. pylori was
inoculated on the agar. After 3-day incubation at 37
oC,
the IgY concentration fully inhibiting the bacterial
growth was determined to be minimal inhibitory
concentration (MIC).
Animals and treatment
Male C57BL/6 mice (body weights 20-24 g) were
procured from Daehan Biolink (Eumseong, Korea), and
housed in a room with constant environmental conditions
(22±2
oC; 40-70% relative humidity; 12-hour light-dark
cycle; 150-300 lux brightness). Pellet feed and purified
water were available ad libitum. All the animal experiments
were conducted according to the Standard Operation
Procedures (SOP), and approved by the Institutional
Animal Care and Use Committee of Chungbuk National
University, Korea. For biosafety the investigators were
fully protected with sterilized clothes, masks and gloves
on SOP.
H. pylori infection and treatment
After 24-hour fasting, the mice (n=10/group) were
orally inoculated with H. pylori (1×10
8 CFU/1 mL/
mouse) 3 times at 2-day intervals [17,24]. Fourteen days
later, a part of the animals (2 mice/group) were sacrificed
to confirm infection using CLO Helicobacter-detection
kits (Asan Pharm Co., Ltd., Seoul, Korea). The mice
were orally treated with IgY (50, 100, 200 or 500 mg/kg)
or pantoprazole (30 mg/kg) twice a day for 18 days.
Biopsy and bacterial identification
One day after the final administration, the mice were
sacrificed and their gastric mucosa was biopsied for the
detection of H. pylori. The biopsy samples (3×3c m )
from gastric pylorus were minced and applied to CLO
kits and incubated at 35
oC for 24 hours to examine urease
activity. The reaction (color change) was determined as
negative for bright yellow, false (partially) positive for
thick yellow, or positive for thick (dark) red.
Additional biopsy samples were obtained with a
culture swab and inoculated to a medium containing
20% glycerol for identification of H. pylori as follows:
Oxidase: A colony was collected with a platinum-
loop, and moved to a filter paper. After dropping p-
phenylenediamine dihydrochloride solution, blue change
following indolphenol blue production was determinedAnti-Helicobacter pylori effects of IgY 57
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as positive reaction.
Catalase: The colony grown in selective medium was
placed on a slide, and bubbling following dropping 3%
H2O2 was determined as positive reaction.
Nitrate reduction: Cultured colony was inoculated to
nitrate broth, and incubated at 35
oC for 48 hours.
Reddish purple change by adding α-naphthylamine and
sulfanilic acid was determined as positive reaction.
H2S formation: The central portion of a colony was
collected with a platinum-loop, and spread on the slant
Triple sugar iron (TSI) medium. Black change following
incubation at 37
oC for 24 hours with the lead open was
determined as positive reaction producing H2S.
Histopathological examination
Stomach was removed and fixed in neutral formalin
solution. Paraffin-embedded tissue slides were stained
with hematoxylin-eoson, and examined under a light
microscope for the inflammatory lesions.
Statistical analysis
Data were expressed as the mean±SEM. Statistical
analysis was performed using an analysis of variance
(ANOVA) with the aid of SPSS for Windows v.10.0
(Chicago, Illinois, USA). A P value <0.05 was considered
statistically significant.
Results
Anti-bacterial activity
In vitro anti-bacterial test, 16 mg/mL and higher
concentrations of IgY completely inhibited the growth of
H. pylori following 3-day incubation of the bacteria
(1×10
8 CFU/mL) with a serially diluted IgY (Table 1).
Therefore, MIC of IgY was determined to be 16 mg/mL,
which was much higher than MIC of pantoprazole
(2.2 mg/mL).
CLO kit test
Repeated intragastric inoculation (1×10
8  CFU, 3
times) of H. pylori to C57BL/6 mice revealed positive
reaction (red color) in CLO test 14 days after the final
inoculation, indicative of the bacterial infection in the
stomach.
The mice orally treated with 50, 100, 200 or 500 mg/
kg IgY twice a day for 18 days displayed positive
reaction in 75% (6/8), 50% (4/8), 12.5% (1/8) and 12.5%
(1/8) mice, respectively, in comparison with 100% (8/8)
positivity at control (vehicle) group (Table 2). Although
there was one case each in 200 and 500 mg/kg IgY
group, no bacteria was detected in bacterial identification
study. By comparison, 25% (2/8) positive reaction was
achieved following treatment with pantoprazole (30 mg/
kg).
Culture of gastric mucosa
From the culture of gastric mucosal specimen to
confirm the presence of H. pylori, bacteria grew in all the
samples from mice (100%) treated with vehicle (Table
3). However, IgY treatment decreased the detection ratio
in a dose-dependent manner, leading to 70, 50, 12.5, and
12.5% at 50, 100, 200 and 500 mg/kg, respectively.
Notably, there was no bacterial growth from the specimens
that displayed partially positive reaction in CLO test. By
comparison, pantoprazole (30 mg/kg) also reduced the
detection ratio of bacterial growth to 25%.
H. pylori identification
The colonies grown from the gastric specimen were
identified whether they are H. pylori. In urease test, all
Table 1. Minimum inhibitory concentration (MIC) of egg york
(IgY) and pantoprazole
Test materials MIC
IgY 16 mg/mL
Pantoprazole 2.2 mg/mL
Table 2. Reactivity in CLO test on the gastric mucosa of mice infected with H. pylori followed by treatment with egg york IgY or
pantoprazole
T r e a t m e n t  ( m g / k g ) 12345678P o s i t i v e  r a t i o
 Vehicle control ●●●●●●●● 8/8
 +IgY (50) ●●●●●●○○ 6/8
 +IgY (100) ●●●●○○○○ 4/8
 +IgY (200) ●◐○○○○○○ 1/8
 +IgY (500) ●◐○○○○○○ 1/8
 +Pantoprazole (30) ●●○○○○○○ 2/8
○, negative; ◐, partially positive; ●, positive.58 Yun-Hui Yang et al.
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the colonies were identified as H. pylori, as also
confirmed in CLO test. However, all the samples from
mice including normal and vehicle groups exhibited
positive reactivity to oxidase and catalase, regardless of
treatment with IgY or pantoprazole, which might be due
to the enzymes from mucosal tissue or microorganisms
other than infected H. pylori. On the contrary, nitrate
reduction and H2S formation, negative markers of H.
pylori, were negative in all the samples including
normal, vehicle and treated groups, implying that there
were no nitrate-reducing and H2S-producing microorganisms
or tissue enzymes and other agents.
Histopathological findings
H. pylori infection led to degeneration and slough of
gastric villi with severe submocosal infiltration of
inflammatory cells (Figures 1A and 1B). IgY inhibited
the inflammatory lesions, recovering to normal features
with high doses (100-500 mg/kg), although light
detachment of villi was observed at a low dose (50 mg/
kg). Pantoprazole (30 mg/kg) also markedly improved
the villi lesions. However, the histopathological features
were in parallel with the presence of H. pylori as
confirmed in CLO test and identification study.
Discussion
Repeated (3 times) intragastric inoculation of H. pylori
(ATCC49503, 1×10
8 CFU/mouse) to male C57BL/6
mice revealed strong positive reaction in CLO test in
14 days, confirming good settlement of the bacteria.
Interestingly, some normal animals without exposure to
H. pylori displayed a weak (false or partially positive)
reactivity, which may be due to the cross-reaction of
other urease-producing bacteria such as Klebsiella and
Proteus [34].
However, in comparison with the weak reactivity to
ureases from Klebsiella and Proteus that are cytosolic
proteins, CLO test detecting extracellular urease from
Helicobacter is very strong so that the efficacy of the test
is believed to be high. Notably, oxidase and catalase,
positive identification markers of H. pylori, was displayed
positive in normal animals too. Such a phenomenon
might be due to the enzymes from tissues and/or other
microorganisms. In contrast, nitrate reduction H2S
formation, negative identification markers of H. pylori,
was also negative in normal mice, indicating that there
were no nitrate-reducing and H2S-producing microorganisms
or tissue enzymes in the stomach. Such results point out
that oxidase, catalase, nitrate reduction and H2S formation,
besides urease, are not suitable markers for detection of
Table 3. Identification of H. pylori through culture of gastric mucosa from mice infected with H. pylori followed by treatment with egg
york (IgY) or pantoprazole
T r e a t m e n t  ( m g / k g ) 12345678 P o s i t i v e  r a t i o
 V e h i c l e  c o n t r o l ++++++++ 8 / 8
 + I g Y  ( 5 0 ) ++++++- - 6 / 8
 +IgY (100) ++++- - - - 4 / 8
 +IgY (200) + ------- 1 / 8
 +IgY (500) + ------- 1 / 8
 + P a n t o p r a z o l e  ( 3 0 ) + +------ 2 / 8
-, negative; +, positive.
Figure 1. Representative microscopic findings of the gastric
mucosa of mice infected with H. pylori followed by treatment
with IgY (50-200 mg/kg) or pantoprazole (30 mg/kg). Note the
degeneration and sloughing of villi (A) and submocosal
inflammatory cell infiltration (B) in vehicle group, in comparison
with light sloughing of villi at a low (50 mg/kg) dose of IgY (C)
and near-normal features at high doses of IgY (D, 100 mg/kg;
E, 200 mg/kg) or pantoprazole (F, 30 mg/kg).Anti-Helicobacter pylori effects of IgY 59
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H. pylori from biopsy specimens or in tissues. To
overcome such a limitation of identification methods, we
additionally examined the histopathological findings for
the evaluation of H. pylori-induced inflammation and
mucosal injuries including degeneration and sloughing
of villi.
In vitro culture study, IgY exerted a relatively weak
anti-H. pylori activity, with 1 mg/mL of MIC. The
activity of IgY in our study was similar to that of H.
pylori-specific IgY-Hp that inhibited bacterial growth
and urease activity by 40 and 24.6% at 1 mg/mL, and 88
and 84.5% at 10 mg/mL, respectively [35]. In another
study, H. pylori urease-specific IgY-HpU also inhibited
urease activity by 29.9 and 81.7% at 1 and 10 mg/mL,
respectively [36], leading to similar efficacies to IgY in
the present study. On the other hand, IgY-HpUc specific
for UreC subunit of urease exerted higher inhibitory
effects on the growth and urease activity of H. pylori
[37].
Treatment with IgY for 18 days eliminated H. pylori
from the stomach of mice in a dose-dependent manner,
reaching 87.5% at 200 or 500 mg/kg. Such anti-bacterial
and anti-inflammatory effects of IgY seem to be higher
than the efficacy of IgY-Hp that exhibited 50-60% anti-
inflammatory activity at 180 mg/kg in a gerbil model
[35]. Furthermore, the efficacy of IgY was superior to
the  H. pylori-elimination ratio (70%) of IgY-Hp58
specific for 58-kDa H. pylori (Hp) antigen [38]. On the
other hand, it was reported that urease-specific IgY
significantly attenuated gastric inflammation of gerbils
fed at a concentration of 25 mg/g diet [39]. In the present
study, H. pylori infection caused extensive degeneration
and detachment of villi, accompanying severe infiltration
of inflammatory cells. However, such pathological changes
were remarkably recovered following eradication of
bacteria by treatment of IgY or pantoprazole. It is of
interest to note that bacterial identification was
impossible in the animals showed partially-positive
reaction in CLO test, which might be due to the urease
released from the bodies or debris of dead H. pylori.
In previous studies, in vivo  H. pylori-eliminating
capacity of IgY specific for urease or subunit of urease
has been demonstrated [37,40-42]. However, since the
titer of such antibodies tended to rapidly decrease at low
pH, researches has focused on their efficacy in the
stomach [40,43]. Indeed, urease-specific IgY did not
completely elliminated H. pylori from human patients,
even though it markedly reduced expiratory urea
concentration by alleviating gastritis and inhibiting
urease activity [43,44]. Thus, human trial for our IgY is
necessary to assess its clinical efficacy. Furthermore,
since synergistic effects in anti-bacterial and anti-
inflammatory activities between IgY and lansoprazole or
famotidine were achieved [39,44,45], combinational
therapy of IgY and traditional drugs is also recommended.
In the present study, it was found that IgY inhibit the
growth of H. pylori with 16 mg/mL of MIC, and
improve gastritis and villi injuries by eliminating the
bacteria from the stomach of mice. The results indicate
that IgY could be a good candidate overcoming
tolerance of antibiotics for the treatment of H. pylori-
mediated gastric ulcers.
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